Table 1.
Association of demographics and preoperative situation for non-AKI group an AKI group.
Table 2.
Association of operative strategy for non-AKI group and AKI group.
Fig 1.
Kinetics of cfDNA/NETs and NGAL in patients undergoing cardiac surgery with CPB.
cfDNA (A) and NGAL (B) levels were quantified in plasma of patients with (n = 21,) or without (n = 37) postoperative AKI development at the indicated times. &p<0.05, §p<0.01, #p<0.001 vs. admission; *p<0.05, **p<0.01, ***p<0.001.
Fig 2.
ROC curves at admission, post-surgery, day 1, day 2 and day 3 for AKI prediction.
Table 3.
Diagnostic accuracy of cfDNA, NGAL and creatinine for predicting AKI after on-pump surgery.
Fig 3.
Kinetics of cfDNA/NETs, NGAL and creatinine in patients with early and late postoperative AKI development.
AKI patients were divided into those with diagnosed AKI during the first 24 hours after surgery (early AKI) and those with AKI development at later times (late AKI). cfDNA (A), NGAL (B) and creatinine (C) concentrations were quantified at the defined times. &p<0.05, §p<0.01, #p<0.001 vs. admission; *p<0.05.
Fig 4.
Association of disease severity and mortality with cfDNA and NGAL.
(A) cfDNA and NGAL were compared between patients with stage 1 (n = 14) and stage 2(n = 7) AKI. Receiver operating characteristic curves were performed for the prediction of tsgae 2 AKI. (B) cfDNA and NGAL levels in patients in survivors and patients who died during 1-year follow-up. Receiver operating characteristic curves were performed for the prediction of mortality in AKI patients.
Table 4.
Predictors for postoperative occurrence of AKI.
Odds ratios refer to cfDNA values greater than threshold for AKI development.
Table 5.
Predictors for postoperative occurrence of AKI.
Odds ratios refer to NGAL values greater than threshold for AKI development.